The development and use of drugs which target the pro-survival members of the Bcl-2 family such as Bcl-2 and Bcl-xL is becoming an increasingly common strategy to combat intrinsic resistance to first line chemotherapy in multiple cancer types [13,14,15,16,17]. The gene discussed is BCL2L1; the disease is cancer.